VANCOUVER, BC--(Marketwire - April 28, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today reported that the company's novel drug candidates to treat malaria have demonstrated good safety in their first toxicity tests in animals. Researchers reported that Upstream's anti-malarial candidates were well tolerated, with no signs of serious toxicity at likely therapeutic dosages suggested by initial in vitro efficacy experiments. Upstream reported in February that these initial efficacy tests suggested anti-malarial activity in the nanomolar range. Activity in this range in a new class of anti-malarial drugs has the potential to represent an important advance in the treatment of resistant disease.
